MedTrace Logo

Effect of Different SARS-CoV-2 Vaccine Schedules and Vaccination Intervals on Reactogenicity and Humoral Immunogenicity

NCT05076227 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1206

Last updated 2022-12-30

No results posted yet for this study

Summary

Investigation of the reactogenicity and immunogenicity of homologous and heterologous vaccine combinations with regard to the formation of SARS-CoV-2 antispike antibodies in health care workers after basic immunization and boost vaccination

Conditions

  • SARS-CoV2 Infection
  • Immunisation Reaction
  • Antibody Hypersensitivity
  • Tolerance

Interventions

DRUG

IM injection of vaccination (mRNA vaccination)

mRNA vaccination

DRUG

IM injection of vaccination (vector based vaccination)

vector based vaccination

Sponsors & Collaborators

  • Serge Thal

    lead OTHER

Principal Investigators

  • Serge C Thal, MD · University of Witten/Herdecke

  • Michael Dedroogh, MD · Helios Clinical Hildesheim

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-30
Primary Completion
2022-03-27
Completion
2022-03-27

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05076227 on ClinicalTrials.gov